

**Review Form 1.6**

Journal Name:	<a href="#">Journal of Pharmaceutical Research International</a>
Manuscript Number:	Ms_JPRI_85510
Title of the Manuscript:	Sensitive and selective analytical method for the quantification of two potential Genotoxic impurities in Azilsartan drug substance by using LC-MS/MS with Multiple Reaction Monitoring(MRM mode)
Type of the Article	

**General guideline for Peer Review process:**

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://www.journalpri.com/index.php/JPRI/editorial-policy>)

**PART 1: Review Comments**

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b><u>Compulsory</u></b> REVISION comments	<p><b>This is actually a reasonable study to assess the accuracy of</b> LC-MS/MS Multiple reaction monitoring (MRM) mode in detecting impurities present before and during synthesis of the drug Azilsartan. Unfortunately it is poorly written up and at present is too confusing for publication.</p> <p><b>1.</b> Abstract must be written to address a) aim of study b) methodology including primary and secondary end-points, how samples were taken, how analysis was carried out, how many times it was repeated, and the statistical analysis done c) results presenting figures and percentages d) conclusion. Each section listed above can be addressed by one or two sentences but must be addressed sequentially in the abstract</p> <p><b>2.</b> The article write up should follow the outline above as for the abstract. It is very important not to jump from one section of the write up to another, so that readers can follow the logic of the study. The aim of study as well as methodology (including primary and secondary end-points, how samples were taken, how analysis was carried out) must be highlighted and defined before any reference to its results (impurities A and B).</p> <p><b>3.</b> It is important to give the chemical structure of each impurity early in the text especially since they are "key starting material for and during synthesis of Azilsartan drug". The chemical structure must be mention in the Introduction or Methodology of the text, with use of the terms impurity-A and impurity-B in brackets. It is only after this clear definition of impurity-A and impurity-B that they written as stand alone words.</p> <p><b>4.</b> There are too many subheading in the methodology and results sections. Authors should try to simplify these.</p>	
<b><u>Minor</u></b> REVISION comments		
<b><u>Optional/General</u></b> comments		

[Review Form 1.6](#)

**PART 2:**

	Reviewer's comment	Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

Reviewer Details:

Name:	Choong Yoke Leng
Department, University & Country	HT Ong Heart Clinic, Malaysia